ノバルティスのインスタグラム(novartis) - 5月27日 19時00分
For decades, doctors had focused on the location of tumors in the body rather than the specific mutations spurring their growth. Oncologists were accustomed to treating tumors with radiation and chemotherapy.
.
.
.
In 2010, researchers at Novartis had an experimental compound they thought would benefit cancer patients. They had a strong hunch, based on their research so far, that the cancer patients most likely to benefit had cancer with a mutation in a specific gene, so they designed a clinical trial to test the drug in exactly those patients.
.
.
.
Back then, most cancer centers weren’t equipped to sequence the genes of their patients’ tumors and identify mutations. The Novartis team moved forward with their trial despite the challenge. Now, after another ten years of research and development, the compound is approved for certain breast cancer patients with this specific mutation.
.
.
.
Christine Fritsch, director of drug discovery biology at the Novartis Institutes for BioMedical Research (NIBR) and a key member of the drug discovery team, thinks this could be a step toward more personalized approach for breast cancer.
[BIHAKUEN]UVシールド(UVShield)
>> 飲む日焼け止め！「UVシールド」を購入する
1,072
19
2019/5/27
